Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namodenoson in advanced hepatocellular carcinoma
NCT00790218Phase 2Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Feb 2009
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of namodenoson in hepatocellular carcinoma (HCC) (3 arms), sponsored by Can-Fite BioPharma Ltd. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Feb 2009; status: completed.
02
Drugs
namodenoson
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00790218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00790218.